Changes to the Code
H.R. 4709 · Newborn Screening Saves Lives Reauthorization Act of 2025 · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
Introduced · step 1 of 5
42 U.S.C. § 300b–8 Improved newborn and child screening for heritable disorders
6 changes the bill asks for here, 5 carried out
- Carried out:
in paragraph (1), by striking
enhance, improve or
and insertingfacilitate, enhance, improve, or
; - Carried out:
by amending paragraph (3) to read as follows:
(3) to develop, and deliver to parents, families, and patient advocacy and support groups, educational programs that— (A) address newborn screening counseling, testing (including newborn screening pilot studies), follow-up, treatment, specialty services, and long-term care; (B) …
- Carried out:
by striking
followup
and insertingfollow-up
; and - Not carried out:
by inserting before the semicolon at the end the following:
, including re-engaging patients who have not received recommended follow-up services and supports
.The bill goes by “;” at the end of § 300b–8(a)(4), but the text there doesn't end with it. The law may have changed since the bill was drafted.
Technical detail
“;” not found at the end of /us/usc/t42/s300b–8/a/4 - Carried out:
by striking
or will use
and insertingwill use
; and - Carried out:
by inserting
, or will use amounts received under such grant to enhance capacity and infrastructure to facilitate the adoption of,
beforethe guidelines and recommendations
.
§ 300b–8(a)
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| § 300b–8. Improved newborn and child screening for heritable disorders | § 300b–8. Improved newborn and child screening for heritable disorders | |||
| (a) | (a) Authorization of grant program | (a) Authorization of grant program | ||
| From amounts appropriated under section 300b–16 of this title, the Secretary, acting through the Administrator of the Health Resources and Services Administration (referred to in this section as the “Administrator”) and taking into consideration the expertise of the Advisory Committee on Heritable Disorders in Newborns and Children (referred to in this section as the “Advisory Committee”), shall award grants to eligible entities to enable such entities— | From amounts appropriated under section 300b–16 of this title, the Secretary, acting through the Administrator of the Health Resources and Services Administration (referred to in this section as the “Administrator”) and taking into consideration the expertise of the Advisory Committee on Heritable Disorders in Newborns and Children (referred to in this section as the “Advisory Committee”), shall award grants to eligible entities to enable such entities— | |||
| (a)(1) | (1) | (1) | ||
| to enhance, improve or expand the ability of State and local public health agencies to provide screening, counseling, or health care services to newborns and children having or at risk for heritable disorders; | to [inserted: facilitate, ]enhance, improve[inserted: ,] or expand the ability of State and local public health agencies to provide screening, counseling, or health care services to newborns and children having or at risk for heritable disorders; | |||
| (a)(2) | (2) | (2) | ||
| to assist in providing health care professionals and newborn screening laboratory personnel with education in newborn screening, counseling, and training in— | to assist in providing health care professionals and newborn screening laboratory personnel with education in newborn screening, counseling, and training in— | |||
| (a)(2)(A) | (A) | (A) | ||
| relevant and new technologies in newborn screening and congenital, genetic, and metabolic disorders; | relevant and new technologies in newborn screening and congenital, genetic, and metabolic disorders; | |||
| (a)(2)(B) | (B) | (B) | ||
| the importance of the timeliness of collection, delivery, receipt, and screening of specimens; and | the importance of the timeliness of collection, delivery, receipt, and screening of specimens; and | |||
| (a)(2)(C) | (C) | (C) | ||
| sharing of medical and diagnostic information with providers and families; | sharing of medical and diagnostic information with providers and families; | |||
| (a)(3) | (3) | (3) | ||
| [inserted: to develop, and deliver to parents, families, and patient advocacy and support groups, educational programs that—] | ||||
| (a)(3)(A) | (A) [inserted: ] | |||
| [inserted: address newborn screening counseling, testing (including newborn screening pilot studies), follow-up, treatment, specialty services, and long-term care;] | ||||
| (a)(3)(B) | (B) [inserted: ] | |||
| [inserted: assess the target audience’s current knowledge, incorporate health communications strategies, and measure impact; and] | ||||
| (a)(3)(C) | (C) [inserted: ] | |||
| [inserted: are at appropriate literacy levels;] | ||||
| (a)(3) | ||||
| (a)(4) | (4) | (4) | ||
| to establish, maintain, and operate a system to assess and coordinate | to establish, maintain, and operate a system to assess and coordinate [inserted: follow-up] and treatment relating to congenital, genetic, and metabolic disorders; and | |||
| (a)(5) | (5) | (5) | ||
| to improve the timeliness of— | to improve the timeliness of— | |||
| (a)(5)(A) | (A) | (A) | ||
| the collection, delivery, receipt, and screening of specimens; and | the collection, delivery, receipt, and screening of specimens; and | |||
§ 300b–8(b)–(e)
(a)(5)(B)–(b)(4) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (b)(5) | (5) | (5) | ||
| any other entity with appropriate expertise in newborn screening, as determined by the Secretary. | any other entity with appropriate expertise in newborn screening, as determined by the Secretary. | |||
| (c) | (c) Approval factors | (c) Approval factors | ||
| An application for a grant under this section shall not be approved by the Secretary unless the application contains assurances that the eligible entity has adopted and implemented, is in the process of adopting and implementing, | An application for a grant under this section shall not be approved by the Secretary unless the application contains assurances that the eligible entity has adopted and implemented, is in the process of adopting and implementing, will use amounts received under such grant to adopt and implement [inserted: , or will use amounts received under such grant to enhance capacity and infrastructure to facilitate ]the [inserted: adoption of, the ]guidelines and recommendations of the Advisory Committee that are adopted by the Secretary and in effect at the time the grant is awarded or renewed under this section, which shall include the screening of each newborn for the heritable disorders recommended by the Advisory Committee and adopted by the Secretary. | |||
| (d) | (d) Coordination | (d) Coordination | ||
| The Secretary shall take all necessary steps to coordinate programs funded with grants received under this section and to coordinate with existing newborn screening activities. | The Secretary shall take all necessary steps to coordinate programs funded with grants received under this section and to coordinate with existing newborn screening activities. | |||
| (e) | (e) Limitation | (e) Limitation | ||
| An eligible entity may not use amounts received under this section to— | An eligible entity may not use amounts received under this section to— |
Rest of § 300b–8 unchanged
42 U.S.C. § 300b–10 Advisory Committee on Heritable Disorders in Newborns and Children
8 changes the bill asks for here, 8 carried out
- Carried out:
in paragraph (5), by inserting
and adopt process improvements
aftertake appropriate steps
; - Carried out:
in paragraph (7) by striking
and
at the end; - Carried out:
by redesignating paragraph (8) as paragraph (9);
- Carried out:
by inserting after paragraph (7) the following:
(8) develop, maintain, and publish on a publicly accessible website consumer-friendly materials detailing— (A) the uniform screening panel nomination process, including data requirements, standards, and the use of international data in nomination submissions; and (B) the process …
- Carried out:
by redesignating subparagraphs (K) and (L) as subparagraphs (L) and (M), respectively; and
- Carried out:
by inserting after subparagraph (J) the following:
(K) the appropriate and recommended use of safe and effective genetic testing by health care professionals in newborns and children with an initial diagnosis of a disease or condition characterized by a variety of genetic causes and manifestations;; and
- Carried out:
in paragraph (1) by striking
2019
and inserting2030
; and - Carried out:
in paragraph (2) by striking
2019
and inserting2030
.
§ 300b–10(b)–(c)
Start of § 300b–10 to (b)(3) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (b)(4) | (4) | (4) | ||
| provide technical assistance, as appropriate, to individuals and organizations regarding the submission of nominations to the uniform screening panel, including prior to the submission of such nominations; | provide technical assistance, as appropriate, to individuals and organizations regarding the submission of nominations to the uniform screening panel, including prior to the submission of such nominations; | |||
| (b)(5) | (5) | (5) | ||
| take appropriate steps, at its discretion, to prepare for the review of nominations prior to their submission, including for conditions for which a screening method has been validated but other nomination criteria are not yet met, in order to facilitate timely action by the Advisory Committee once such submission has been received by the Committee; | take appropriate steps[inserted: and adopt process improvements], at its discretion, to prepare for the review of nominations prior to their submission, including for conditions for which a screening method has been validated but other nomination criteria are not yet met, in order to facilitate timely action by the Advisory Committee once such submission has been received by the Committee; | |||
| (b)(6) | (6) | (6) | ||
| develop a model decision-matrix for newborn screening expansion, including an evaluation of the potential public health impact, including the cost of such expansion, and periodically update the recommended uniform screening panel, as appropriate, based on such decision-matrix; | develop a model decision-matrix for newborn screening expansion, including an evaluation of the potential public health impact, including the cost of such expansion, and periodically update the recommended uniform screening panel, as appropriate, based on such decision-matrix; | |||
| (b)(7) | (7) | (7) | ||
| consider ways to ensure that all States attain the capacity to screen for the conditions described in paragraph (3), and include in such consideration the results of grant funding under section 300b–8 of this title; | consider ways to ensure that all States attain the capacity to screen for the conditions described in paragraph (3), and include in such consideration the results of grant funding under section 300b–8 of this title; | |||
| (b)(8) | (8) [inserted: ] | |||
| [inserted: develop, maintain, and publish on a publicly accessible website consumer-friendly materials detailing—] | ||||
| (b)(8)(A) | (A) [inserted: ] | |||
| [inserted: the uniform screening panel nomination process, including data requirements, standards, and the use of international data in nomination submissions; and] | ||||
| (b)(8)(B) | (B) [inserted: ] | |||
| [inserted: the process for obtaining technical assistance for submitting nominations to the uniform screening panel and detailing the instances in which the provision of technical assistance would introduce a conflict of interest for members of the Advisory Committee; and] | ||||
| (b)(9) | [inserted: (9)] | |||
| provide such recommendations, advice or information as may be necessary to enhance, expand or improve the ability of the Secretary to reduce the mortality or morbidity from heritable disorders, which may include recommendations, advice, or information dealing with— | provide such recommendations, advice or information as may be necessary to enhance, expand or improve the ability of the Secretary to reduce the mortality or morbidity from heritable disorders, which may include recommendations, advice, or information dealing with— | |||
| (b)(9)(A) | (A) | (A) | ||
| follow-up activities, including those necessary to achieve best practices in rapid diagnosis and appropriate treatment in the short-term, and those that ascertain long-term case management outcomes and appropriate access to related services; | follow-up activities, including those necessary to achieve best practices in rapid diagnosis and appropriate treatment in the short-term, and those that ascertain long-term case management outcomes and appropriate access to related services; | |||
| (b)(9)(B) | (B) | (B) | ||
| implementation, monitoring, and evaluation of newborn screening activities, including diagnosis, screening, follow-up, and treatment activities; | implementation, monitoring, and evaluation of newborn screening activities, including diagnosis, screening, follow-up, and treatment activities; | |||
| (b)(9)(C) | (C) | (C) | ||
| diagnostic and other technology used in screening; | diagnostic and other technology used in screening; | |||
| (b)(9)(D) | (D) | (D) | ||
| the availability and reporting of testing for conditions for which there is no existing treatment, including information on cost and incidence; | the availability and reporting of testing for conditions for which there is no existing treatment, including information on cost and incidence; | |||
| (b)(9)(E) | (E) | (E) | ||
| conditions not included in the recommended uniform screening panel that are treatable with Food and Drug Administration-approved products or other safe and effective treatments, as determined by scientific evidence and peer review; | conditions not included in the recommended uniform screening panel that are treatable with Food and Drug Administration-approved products or other safe and effective treatments, as determined by scientific evidence and peer review; | |||
| (b)(9)(F) | (F) | (F) | ||
| minimum standards and related policies and procedures used by State newborn screening programs, such as language and terminology used by State newborn screening programs to include standardization of case definitions and names of disorders for which newborn screening tests are performed; | minimum standards and related policies and procedures used by State newborn screening programs, such as language and terminology used by State newborn screening programs to include standardization of case definitions and names of disorders for which newborn screening tests are performed; | |||
| (b)(9)(G) | (G) | (G) | ||
| quality assurance, oversight, and evaluation of State newborn screening programs, including ensuring that tests and technologies used by each State meet established standards for detecting and reporting positive screening results; | quality assurance, oversight, and evaluation of State newborn screening programs, including ensuring that tests and technologies used by each State meet established standards for detecting and reporting positive screening results; | |||
| (b)(9)(H) | (H) | (H) | ||
| public and provider awareness and education; | public and provider awareness and education; | |||
| (b)(9)(I) | (I) | (I) | ||
| the cost and effectiveness of newborn screening and medical evaluation systems and intervention programs conducted by State-based programs; | the cost and effectiveness of newborn screening and medical evaluation systems and intervention programs conducted by State-based programs; | |||
| (b)(9)(J) | (J) | (J) | ||
| identification of the causes of, public health impacts of, and risk factors for heritable disorders; | identification of the causes of, public health impacts of, and risk factors for heritable disorders; | |||
| (b)(9)(K) | (K) [inserted: ] | |||
| [inserted: the appropriate and recommended use of safe and effective genetic testing by health care professionals in newborns and children with an initial diagnosis of a disease or condition characterized by a variety of genetic causes and manifestations;] | ||||
| (b)(9)(L) | [inserted: (L)] | |||
| coordination of surveillance activities, including standardized data collection and reporting, harmonization of laboratory definitions for heritable disorders and testing results, and confirmatory testing and verification of positive results, in order to assess and enhance monitoring of newborn diseases; and | coordination of surveillance activities, including standardized data collection and reporting, harmonization of laboratory definitions for heritable disorders and testing results, and confirmatory testing and verification of positive results, in order to assess and enhance monitoring of newborn diseases; and | |||
| (b)(9)(M) | [inserted: (M)] | |||
| the timeliness of collection, delivery, receipt, and screening of specimens to be tested for heritable disorders in newborns in order to ensure rapid diagnosis and followup. | the timeliness of collection, delivery, receipt, and screening of specimens to be tested for heritable disorders in newborns in order to ensure rapid diagnosis and followup. | |||
| (c) | (c) Membership | (c) Membership | ||
| (c)(1) | (1) In general | (1) In general | ||
| The Secretary shall appoint not to exceed 15 members to the Advisory Committee. In appointing such members, the Secretary shall ensure that the total membership of the Advisory Committee is an odd number. | The Secretary shall appoint not to exceed 15 members to the Advisory Committee. In appointing such members, the Secretary shall ensure that the total membership of the Advisory Committee is an odd number. | |||
§ 300b–10(f)–(g)
(c)(2)–(e)(3) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (f) | (f) Meetings | (f) Meetings | ||
| The Advisory Committee shall meet at least 4 times each calendar year, or at the discretion of the Designated Federal Officer in consultation with the Chair. | The Advisory Committee shall meet at least 4 times each calendar year, or at the discretion of the Designated Federal Officer in consultation with the Chair. | |||
| (g) | (g) Continuation of operation of Committee | (g) Continuation of operation of Committee | ||
| (g)(1) | (1) In general | (1) In general | ||
| Notwithstanding section 1013 of title 5, the Advisory Committee shall continue to operate through the end of fiscal year | Notwithstanding section 1013 of title 5, the Advisory Committee shall continue to operate through the end of fiscal year [inserted: 2030]. | |||
| (g)(2) | (2) Continuation if not reauthorized | (2) Continuation if not reauthorized | ||
| If at the end of fiscal year | If at the end of fiscal year [inserted: 2030] the duration of the Advisory Committee has not been extended by statute, the Advisory Committee may be deemed, for purposes of chapter 10 of title 5, an advisory committed established by the President or an officer of the Federal Government under section 1008(a) of title 5. |
42 U.S.C. § 300b–11 Clearinghouse of newborn screening information
1 change the bill asks for here, 1 carried out
- Carried out:
Section 1112(c) of the Public Health Service Act (42 U.S.C. 300b–11(c)) is amended by striking
and supplement, not supplant, existing information sharing efforts
and insertingand complement other Federal newborn screening information sharing activities
.
§ 300b–11(b)–(c)
Start of § 300b–11 to (b)(4)(D) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (b)(4)(E) | (E) | (E) | ||
| other relevant information as determined appropriate by the Secretary. | other relevant information as determined appropriate by the Secretary. | |||
| (c) | (c) Nonduplication | (c) Nonduplication | ||
| In carrying out activities under this section, the Secretary shall ensure that such activities minimize duplication and | In carrying out activities under this section, the Secretary shall ensure that such activities minimize duplication and [inserted: complement] [inserted: other] [inserted: Federal] [inserted: newborn] [inserted: screening ]information sharing [inserted: activities]. |
42 U.S.C. § 300b–12 Laboratory quality and surveillance
6 changes the bill asks for here, 5 carried out
- Carried out:
by striking
performance evaluation services,
and insertingdevelopment of new screening tests,
; and - Carried out:
by striking
and
at the end; - Carried out:
by striking
performance test materials
and insertingtest performance materials
; and - Carried out:
by striking the period at the end and inserting
; and
; and - Carried out:
by adding at the end the following:
(3) performance evaluation services to enhance disease detection, including the development of tools, resources, and infrastructure to improve data analysis, test result interpretation, data harmonization, and dissemination of laboratory best practices.; and
- Not carried out:
in subsection (b) to read as follows:
(b) Surveillance activities.— The Secretary, acting through the Director of the Centers for Disease Control and Prevention, and taking into consideration the expertise of the Advisory Committee on Heritable Disorders in Newborns and Children established under section 1111, shall …
We can't read how this instruction is worded yet, so it isn't shown in the text.
Technical detail
no-pattern: to read as follows: QCONTENT.
§ 300b–12(a)–(b)
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| § 300b–12. Laboratory quality and surveillance | § 300b–12. Laboratory quality and surveillance | |||
| (a) | (a) In general | (a) In general | ||
| The Secretary, acting through the Director of the Centers for Disease Control and Prevention and taking into consideration the expertise of the Advisory Committee on Heritable Disorders in Newborns and Children established under section 300b–10 of this title, shall provide for— | The Secretary, acting through the Director of the Centers for Disease Control and Prevention and taking into consideration the expertise of the Advisory Committee on Heritable Disorders in Newborns and Children established under section 300b–10 of this title, shall provide for— | |||
| (a)(1) | (1) | (1) | ||
| quality assurance for laboratories involved in screening newborns and children for heritable disorders, including quality assurance for newborn-screening tests, timeliness for processing such tests, | quality assurance for laboratories involved in screening newborns and children for heritable disorders, including quality assurance for newborn-screening tests, timeliness for processing such tests, [inserted: development] [inserted: of] [inserted: new screening tests], and technical assistance and technology transfer to newborn screening laboratories to ensure analytic validity and utility of screening tests; | |||
| (a)(2) | (2) | (2) | ||
| appropriate quality control and other | appropriate quality control and other test [inserted: performance ]materials to evaluate the performance of new screening tools[inserted: ; and] | |||
| (a)(3) | (3) [inserted: ] | |||
| [inserted: performance evaluation services to enhance disease detection, including the development of tools, resources, and infrastructure to improve data analysis, test result interpretation, data harmonization, and dissemination of laboratory best practices.] | ||||
| (b) | (b) Surveillance activities | (b) Surveillance activities | ||
| The Secretary, acting through the Director of the Centers for Disease Control and Prevention, and taking into consideration the expertise of the Advisory Committee on Heritable Disorders in Newborns and Children established under section 300b–10 of this title, may provide, as appropriate, for the coordination of surveillance activities, including— | The Secretary, acting through the Director of the Centers for Disease Control and Prevention, and taking into consideration the expertise of the Advisory Committee on Heritable Disorders in Newborns and Children established under section 300b–10 of this title, may provide, as appropriate, for the coordination of surveillance activities, including— | |||
| (b)(1) | (1) | (1) | ||
| through standardized data collection and reporting, as well as the use of electronic health records; and | through standardized data collection and reporting, as well as the use of electronic health records; and | |||
| (b)(2) | (2) | (2) | ||
| by promoting data sharing regarding newborn screening with State-based birth defects and developmental disabilities monitoring programs. | by promoting data sharing regarding newborn screening with State-based birth defects and developmental disabilities monitoring programs. | |||
42 U.S.C. § 300b–15 Hunter Kelly Research Program
4 changes the bill asks for here, 3 carried out
- Carried out:
by striking
may
and insertingshall
; and - Carried out:
by inserting
, or with a high probability of being recommended by,
afterrecommended by
; and - Carried out:
by striking
that screenings are ready for nationwide implementation
and insertingthat reliable newborn screening technologies are piloted and ready for use
; and - Not carried out:
in subsection (b) to read as follows:
(b) Funding.— In carrying out the research program under this section, the Secretary and the Director shall ensure that entities receiving funding through the program will provide assurances, as practicable, that such entities will work in consultation with State departments of health, as appropriate..
We can't read how this instruction is worded yet, so it isn't shown in the text.
Technical detail
no-pattern: to read as follows: QCONTENT.
§ 300b–15(a)
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| § 300b–15. Hunter Kelly Research Program | § 300b–15. Hunter Kelly Research Program | |||
| (a) | (a) Newborn screening activities | (a) Newborn screening activities | ||
| (a)(1) | (1) In general | (1) In general | ||
| The Secretary, in conjunction with the Director of the National Institutes of Health and taking into consideration the recommendations of the Advisory Committee, | The Secretary, in conjunction with the Director of the National Institutes of Health and taking into consideration the recommendations of the Advisory Committee, [inserted: shall] continue carrying out, coordinating, and expanding research in newborn screening (to be known as “Hunter Kelly Newborn Screening Research Program”) including— | |||
| (a)(1)(A) | (A) | (A) | ||
| identifying, developing, and testing the most promising new screening technologies, in order to improve already existing screening tests, increase the specificity of newborn screening, and expand the number of conditions for which screening tests are available; | identifying, developing, and testing the most promising new screening technologies, in order to improve already existing screening tests, increase the specificity of newborn screening, and expand the number of conditions for which screening tests are available; | |||
| (a)(1)(B) | (B) | (B) | ||
| experimental treatments and disease management strategies for additional newborn conditions, and other genetic, metabolic, hormonal, or functional conditions that can be detected through newborn screening for which treatment is not yet available; | experimental treatments and disease management strategies for additional newborn conditions, and other genetic, metabolic, hormonal, or functional conditions that can be detected through newborn screening for which treatment is not yet available; | |||
| (a)(1)(C) | (C) | (C) | ||
| providing research findings and data for newborn conditions under review by the Advisory Committee on Heritable Disorders in Newborns and Children to be added to the recommended uniform screening panel; | providing research findings and data for newborn conditions under review by the Advisory Committee on Heritable Disorders in Newborns and Children to be added to the recommended uniform screening panel; | |||
| (a)(1)(D) | (D) | (D) | ||
| conducting pilot studies on conditions recommended by the Advisory Committee on Heritable Disorders in Newborns and Children to ensure that | conducting pilot studies on conditions recommended by[inserted: ,] [inserted: or with a high probability of being recommended by, ]the Advisory Committee on Heritable Disorders in Newborns and Children to ensure that [inserted: reliable] [inserted: newborn screening technologies ]are [inserted: piloted and ]ready for [inserted: use]; and | |||
| (a)(1)(E) | (E) | (E) | ||
| other activities that would improve newborn screening, as identified by the Director. | other activities that would improve newborn screening, as identified by the Director. | |||
| (a)(2) | (2) Additional newborn condition | (2) Additional newborn condition | ||
| For purposes of this subsection, the term “additional newborn condition” means any condition that is not one of the core conditions recommended by the Advisory Committee and adopted by the Secretary. | For purposes of this subsection, the term “additional newborn condition” means any condition that is not one of the core conditions recommended by the Advisory Committee and adopted by the Secretary. |
Rest of § 300b–15 unchanged
42 U.S.C. § 300b–16 Authorization of appropriations for newborn screening programs and activities
6 changes the bill asks for here, 6 carried out
- Carried out:
by striking
$11,900,000
and inserting$20,883,000
; - Carried out:
by striking
2015
and inserting2026
; and - Carried out:
by striking
2019
and inserting2030
; and - Carried out:
by striking
$8,000,000
and inserting$22,250,000
; - Carried out:
by striking
2015
and inserting2026
; and - Carried out:
by striking
2019
and inserting2030
.
§ 300b–16(1)–(2)
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| § 300b–16. Authorization of appropriations for newborn screening programs and activities | § 300b–16. Authorization of appropriations for newborn screening programs and activities | |||
| There are authorized to be appropriated— | There are authorized to be appropriated— | |||
| (1) | (1) | (1) | ||
| to carry out sections 300b–8, 300b–9, 300b–10, and 300b–11 of this title, $ | to carry out sections 300b–8, 300b–9, 300b–10, and 300b–11 of this title, $[inserted: 20],[inserted: 883],000 for each of fiscal years [inserted: 2026] through [inserted: 2030]; and | |||
| (2) | (2) | (2) | ||
| to carry out section 300b–12 of this title, $ | to carry out section 300b–12 of this title, $[inserted: 22],[inserted: 250],000 for each of fiscal years [inserted: 2026] through [inserted: 2030]. |